Loading…
Comprehensive Addiction and Recovery Act of 2016
Legislative Progress
Introduced
February 12, 2015
Latest Action
July 22, 2016
Primary Sponsor
Sheldon WhitehouseDemocratic(RI)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
99pct
526d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Comprehensive Addiction and Recovery Act of 2016 TITLE I--PREVENTION AND EDUCATION (Sec. 101) This bill requires the Department of Health and Human Services (HHS), in cooperation with the Department of Veterans Affairs, the Department of Defense, and the Drug Enforcement Administration , to convene a Pain Management Best Practices Interagency Task Force to review, modify, and update best practices for pain management and prescription of pain medication. The task force does not have rulemaking authority. (Sec. 102) It directs HHS to promote education and awareness of prescription opioid abuse. Such education and training must include information on the dangers, prevention, and early warning signs of opioid abuse. (Opioids are drugs with effects similar to opium, such as certain prescription pain medication, fentanyl [a synthetic opioid], and heroin.) The Office of National Drug Control Policy must establish a national drug awareness campaign that addresses the similarities between opioids and heroin, the link between prescription opioid abuse and heroin use, and the dangerous effects of mixing fentanyl with heroin. (Sec. 103) The bill amends the Omnibus Crime Control and Safe Streets Act of 1968 to authorize HHS to award grants to community-based coalitions to enhance community-wide prevention strategies to address a high rate or rapid increase of opioid or methamphetamine abuse. TITLE II--LAW ENFORCEMENT AND TREATMENT (Sec. 201) HHS may award grants to state, local, or tribal governments or nonprofit organizations to develop, implement, or expand treatment alternative to incarceration programs and to enhance state criminal justice and substance abuse agency collaboration to address prescription opioid abuse and heroin use. HHS must give priority to joint applications from criminal justice and substance abuse agencies and applications from states that provide civil liability protection for trained first responders, health professionals, or family members who administer an opioid overdose reversal drug (e.g., naloxone) to counteract opioid overdose. (Sec. 202) HHS may award grants to state, local, or tribal governments to allow appropriately trained first responders to administer an opioid overdose reversal drug to treat an opioid overdose. Grant funds must be used to equip first responders with opioid overdose reversal drugs, train first responders to administer such drugs, and develop protocols to refer overdose victims to appropriate treatment. HHS must provide technical assistance and training grants. At least 25% of grant funds must be awarded to entities in rural areas with limited access to emergency medical services. (Sec. 203) The Department of Justice (DOJ) must expand or make available disposal sites for unwanted prescription medications. (Sec. 204) DOJ may make grants to state law enforcement agencies to investigate illicit activities related to: (1) heroin, fentanyl, or unlawful prescription opioid distribution, and (2) precursor diversion, laboratories, or methamphetamine manufacture or distribution. TITLE III--TREATMENT AND RECOVERY (Sec. 301) The bill authorizes the Substance Abuse and Mental Health Services Administration (SAMHSA) to award grants to state, local, or tribal governments or community-based organizations to expand treatment programs, including medication-assisted treatment programs, in areas with a high rate or rapid increase in prescription opioid or heroin use. SAMHSA must equitably distribute grants geographically, evaluate grant-supported activities, and provide technical assistance. (Sec. 302) HHS may award grants to state, local, or tribal governments to implement medication-assisted treatment programs through courts, prisons, jails, or other criminal justice agencies. HHS must prioritize entities in states that provide civil liability protection for trained first responders, health professionals, or family members who administer naloxone to counteract opioid overdose. Additionally, HHS must provide technical assistance and training to grant recipients. (Sec. 303) HHS may award grants to high schools, institutions of higher education, or nonprofit organizations to provide recovery support services, build supportive communities, and promote sustained recovery for young people with substance use disorders. (Sec. 304) HHS may award matching grants to recovery community organizations to expand, develop, and enhance state and community recovery support services to facilitate long-term recovery from substance use disorders. A recovery community organization is an independent nonprofit organization that is led by individuals who are in long-term recovery from substance abuse disorders. TITLE IV--ADDRESSING COLLATERAL CONSEQUENCES (Sec. 401) The bill authorizes DOJ to award grants to state, local, or tribal governments to design, implement, and expand educational programs for offenders in prisons, jails, and juvenile facilities. A grant recipient may restrict prisoners' Internet access to ensure public safety. (Sec. 402) DOJ must establish a bipartisan Task Force on Recovery and Collateral Consequences to identify collateral consequences imposed on convicted drug offenders who are in recovery for a substance use disorder and develop and submit legislative and regulatory recommendations to modify such collateral consequences. A collateral consequence is a penalty imposed as a result of a criminal conviction but not as part of the court judgment. TITLE V--ADDICTION AND TREATMENT SERVICES FOR WOMEN, FAMILIES, AND VETERANS (Sec. 501) The bill authorizes SAMHSA to create a pilot program to award competitive grants to state substance abuse agencies to support family-based services for pregnant and postpartum women with a substance use disorder, address gaps in services provided to women in non-residential based settings, and encourage evidence-based services. The Center for Behavioral Health Statistics and Quality must evaluate the pilot program and report to Congress. (Sec. 502) DOJ must annually report the number of grant awards under the Family-Based Adult Offender Substance Abuse Treatment Program and how such grants are used for family-based substance abuse treatment programs that serve as an alternative to incarceration for custodial parent drug offenders. TITLE VI--INCENTIVIZING STATE COMPREHENSIVE INITIATIVES TO ADDRESS OPIOID AND HEROIN ABUSE (Sec. 601) DOJ may award grants to states to establish and implement a comprehensive response to opioid abuse that includes prevention and education efforts, a prescription drug monitoring program, prescription drug and opioid addiction treatment programs, and overdose death prevention programs. DOJ must give priority to states that: (1) provide civil liability protection for trained first responders, health professionals, or family members who administer naloxone; (2) do not terminate Medicaid eligibility for individuals who are incarcerated for less than two years; (3) enroll incarcerated drug offenders in community-based treatment services prior to reentry; and (4) record, share, or analyze data from prescription drug monitoring database to identify potential abuse. TITLE VII--MISCELLANEOUS (Sec. 701) The Government Accountability Office must report to Congress on how the Medicaid institutions for mental disease (IMD) exclusion impacts access to inpatient treatment and quality of inpatient and outpatient treatment for Medicaid enrollees with substance use disorders. The Medicaid IMD exclusion bars Medicaid reimbursement for certain inpatient mental health care services (including substance use disorder treatment) for patients aged 21 to 64. (Sec. 702) The bill authorizes addiction and recovery programs under this Act through FY2020. (Sec. 704) It prohibits the use of DOJ and HHS grants under this Act for conferences that cost more than $20,000 without prior written approval. The Inspector General for DOJ and HHS must conduct annual audits of selected grant recipients. It bars DOJ and HHS grants to nonprofit organizations that hold money in an offshore account to avoid tax liability. Additionally, DOJ and HHS must identify and report on duplicative grant awards. (Sec. 705) This bill amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to authorize a Medicare prescription drug plan (PDP) sponsor to establish a drug management program to limit the prescribers and pharmacies who provide frequently abused drugs to an at-risk beneficiary. A PDP sponsor must have in place a utilization management tool to prevent drug abuse. A PDP sponsor must: (1) notify a beneficiary who is identified as being at-risk for prescription drug abuse, (2) consider the beneficiary's preferences in selecting allowable prescribers and pharmacies, and (3) ensure the beneficiary has continued reasonable access to drugs. The bill exempts from identification as at-risk beneficiary an individual who is receiving hospice care or residing in a long-term care facility. HHS must establish procedures for PDP plan sponsors to share information about at-risk beneficiaries. TITLE VIII--TRANSNATIONAL DRUG TRAFFICKING ACT Transnational Drug Trafficking Act of 2015 (Sec. 802) This bill amends the Controlled Substances Import and Export Act to broaden the scope of persons subject to criminal prosecution for manufacturing or distributing a controlled substance in schedule I or II, a precursor chemical, or flunitrazepam for unlawful import into the United States. The Controlled Substances Act classifies drugs, substances, and chemicals used to make drugs into one of five schedules based on the drug's medical use, potential for abuse, and risk of dependence. Current law prohibits such manufacture or distribution by a person who knows or intends that the substance or chemical will be unlawfully imported. This bill broadens the scope to also prohibit such manufacture or distribution by a person who reasonably believes that the substance or chemical will be unlawfully imported. In addition, this bill prohibits the manufacture or distribution of a precursor chemical by a person who: (1) knows or intends that the chemical will be used to manufacture a controlled substance; and (2) knows, intends, or reasonably believes that the controlled substance will be unlawfully imported into the United States. (Sec. 803) The legislation amends the federal criminal code to replace statutory references to prohibited trafficking in a "counterfeit drug" with references to prohibited trafficking in a "drug that uses a counterfeit mark on or in connection with the drug."
Yes
689
No
62
Present
0
Not Voting
49
Party Breakdown
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (174)
Became Public Law No: 114-198.
Became Public Law No: 114-198.
Signed by President.
Signed by President.
Presented to President.
Presented to President.
Message on Senate action sent to the House.
Senate agreed to conference report to accompany S. 524 by Yea-Nay Vote. 92 - 2. Record Vote Number: 129.
SenateConference report agreed to in Senate: Senate agreed to conference report to accompany S. 524 by Yea-Nay Vote. 92 - 2. Record Vote Number: 129.
SenateCloture on the conference report to accompany S. 524 invoked in Senate by Yea-Nay Vote. 90 - 2. Record Vote Number: 126. (consideration: CR S5027-5028; text: CR S5027)
SenateBills with similar content found using semantic analysis.
Sources: Congress.gov · House Clerk roll-call votes
| #126 | senate | On the Cloture Motion | Cloture Motion Agreed to (90-2, 3/5 majority required) | July 13, 2016 |
| #129 | senate | On the Conference Report | Conference Report Agreed to (92-2) | July 13, 2016 |
| #101 | senate | On the Motion | Motion Agreed to (66-29) | June 16, 2016 |
| #100 | senate | On the Cloture Motion | Cloture Motion Agreed to (95-1, 3/5 majority required) | June 16, 2016 |
| #102 | senate | On the Motion | Motion Agreed to (70-24) | June 16, 2016 |
| #34 | senate | On Passage of the Bill | Bill Passed (94-1) | March 10, 2016 |
| #33 | senate | On the Cloture Motion | Cloture Motion Agreed to (93-3, 3/5 majority required) | March 9, 2016 |
| #27 | senate | On Cloture on the Motion to Proceed | Cloture on the Motion to Proceed Agreed to (89-0, 3/5 majority required) | February 29, 2016 |
2019 · third_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · second_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · first_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · fourth_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · fourth_quarter · Health Issues
HCR: HCR: Implementation of health care reform law as it relates to substance abuse treatment and prevention, Medicaid - IMD exclusion; parity for SUD treatment; S. 524, access to treatment under Medicaid and Essential health benefits the Comprehensive Addiction & Recovery Act, specifically provisions that relate to SUD Treatment. S.1169 Medcaid Coverage for Addiction Recovery Expansion (Medicaid CARE) act , H.R. 2938 Road to Recovery Act, H.R. 2687 Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act; monitoring policies and regulations related to the Presidents declaration of the opioid crisis as a public health emergency under the Public Health Service Act; H.R. 5797 Legislation to reform IMD exclusion; Provisions related to IMD exclusion in HR 6 and enacted into law as the SUPPORT for Patients and Communities Act, designated Public Law 115-271. Patient privacy provisions in H.R. 6082, the Overdose Prevention and Patient Safety Act
Client expense: Not reported · Firm income: $10,000
Conference report considered in Senate. (consideration: CR S5022-5028, S5045-5058, S5058-5066)
Conference report considered in Senate. (consideration: CR S4955-4962, S4975-4993)
Cloture motion on the conference report to accompany S. 524 presented in Senate. (consideration: CR S4926; text: CR S4926)
Conference report considered in Senate. (consideration: CR S4926-4929)
Conference papers: Senate report and manager's statement and message on House action held at the desk in Senate.
Motions to reconsider laid on the table Agreed to without objection.
On agreeing to the conference report Agreed to by the Yeas and Nays: 407 - 5 (Roll No. 399). (consideration: CR H4561)
HouseConference report agreed to in House: On agreeing to the conference report Agreed to by the Yeas and Nays: 407 - 5 (Roll No. 399).(consideration: CR H4561)
HouseThe previous question was ordered pursuant to the rule. (consideration: CR H4561)
DEBATE - The House proceeded with one hour of debate on the conference report to accompany S. 524.
Mr. Upton brought up conference report H. Rept. 114-669 for consideration as a privileged matter. (consideration: CR H4554-4561)
CALLING UP CONFERENCE REPORT - Pursuant to the provisions of H. Res. 809, the Chair recognized Mr. Upton for the purpose of calling up the conference report to accompany S. 524.
Rule H. Res. 809 passed House.
Rules Committee Resolution H. Res. 809 Reported to House. Rule provides for consideration of the conference report to S. 524 with 1 hour of general debate. Previous question shall be considered as ordered without intervening motions except motion to recommit. Sec. 2 provides that upon adoption of the resolution, the House shall be considered to have taken S. 2943 from the Speaker's table, stricken all after the enacting clause and inserted the provisions of H.R. 4909 as passed by the House. S. 2943 shall be considered as passed as amended. It shall also be in order for the Chair of the Committee on Armed services to move that the House insist on its amendment to S. 2943 and request a conference with the Senate thereon.
Conference report H. Rept. 114-669 filed. (text of conference report: CR H4392-4419)
Conference report filed: Conference report H. Rept. 114-669 filed.(text of conference report: CR H4392-4419)
Conferees agreed to file conference report.
Conference committee actions: Conferees agreed to file conference report.
Message on Senate action sent to the House.
Motion by Senator Whitehouse to instruct Senate conferees agreed to in Senate by Yea-Nay Vote. 70 - 24. Record Vote Number: 102. (consideration: CR S4284; text: CR S4284)
SenateMotion by Senator Shaheen to instruct Senate conferees agreed to in Senate by Yea-Nay Vote. 66 - 29. Record Vote Number: 101. (consideration: CR S4284; text: CR S4284)
SenateSenate disagrees to the House amendments to the Senate bill, agrees to the request for conference, and the Presiding Officer appoints the following conferees: Grassley, Alexander, Hatch, Sessions, Leahy, Murray, and Wyden.
Motion to disagree to the House amendments to the Senate bill, agree to the request for conference, and the Presiding Officer appoint the following conferees: Grassley, Alexander, Hatch, Sessions, Leahy, Murray, and Wyden agreed to in Senate by Voice Vote.
Cloture on the motion to disagree to the House amendments to the Senate bill, agree to the request for conference, and the Presiding Officer appoint the following conferees: Grassley, Alexander, Hatch, Sessions, Leahy, Murray, and Wyden invoked in Senate by Yea-Nay Vote. 95 - 1. Record Vote Number: 100. (consideration: CR S4283; text: CR S4283)
SenateCloture motion on the motion to disagree to the House amendments to the Senate bill, agree to the request for conference, and the Presiding Officer appoint the following conferees: Grassley, Alexander, Hatch, Sessions, Leahy, Murray, and Wyden presented in Senate. (consideration: CR S4277; text: CR S4277)
Motion to disagree to the House amendments to the Senate bill, agree to the request for conference, and the Presiding Officer appoint the following conferees: Grassley, Alexander, Hatch, Sessions, Leahy, Murray, and Wyden made in Senate. (consideration: CR S4277)
Measure laid before Senate by unanimous consent. (consideration: CR S4277-4285)
Message on House action received in Senate and at desk: House amendments to Senate bill and House requests a conference.
The Speaker appointed conferees - from the Committee on Ways and Means for consideration of sec. 705 of the Senate bill, and sec. 804 of the House amendment, and modifications committed to conference: Meehan, Dold, and McDermott.
The Speaker appointed conferees - from the Committee on Veterans' Affairs for consideration of title III of the House amendment, and modifications committed to conference: Bilirakis, Walorski, and Ruiz.
The Speaker appointed conferees - from the Committee on Education and the Workforce for consideration of title VII of the House amendment, and modifications committed to conference: Barletta, Carter of Georgia, and Scott of Virginia.
The Speaker appointed conferees for consideration of the Senate bill and the House amendments, and modifications committed to conference: Upton, Pitts, Lance, Guthrie, Kinzinger of Illinois, Bucshon, Brooks of Indiana, Goodlatte, Sensenbrenner, Smith of Texas, Marino, Collins of Georgia, Trott, Bishop of Michigan, McCarthy, Pallone, Ben Ray Luján of New Mexico, Sarbanes, Gene Green of Texas, Conyers, Jackson Lee, Judy Chu of California, Cohen, Esty, Kuster, and Courtney.
Motion to reconsider laid on the table Agreed to without objection.
On motion that the House instruct conferees Failed by the Yeas and Nays: 182 - 236 (Roll no. 198).
HouseConsidered as unfinished business. (consideration: CR H2456-2457)
POSTPONED PROCEEDINGS - The Chair put the question on adoption of the motion to instruct conferees and by voice vote, announced that the noes had prevailed. Ms. Esty demanded the yeas and nays and the Chair postponed further proceedings on the question of adoption of the motion until a time to be announced.
The previous question was ordered without objection. (consideration: CR H2376)
DEBATE - The House proceeded with one hour of debate on the Esty motion to instruct conferees. The instructions contained in the motion seek to require the managers on the part of the House to recede to title III of the bill (relating to treatment and recovery programs).
Ms. Esty moved that the House instruct conferees. (consideration: CR H2374-2375; text: CR H2374)
On motion that the House insist upon its amendments, and request a conference Agreed to without objection.
Mrs. Brooks (IN) asked unanimous consent that the House insist upon its amendments, and request a conference. (consideration: CR H2374)
The title of the measure was amended pursuant to H. Res. 725.
Motion to reconsider laid on the table Agreed to without objection.
On passage Passed by the Yeas and Nays: 400 - 5 (Roll no. 193). (text: CR H2355-2368)
HousePassed/agreed to in House: On passage Passed by the Yeas and Nays: 400 - 5 (Roll no. 193).(text: CR H2355-2368)
HouseThe previous question was ordered pursuant to the rule. (consideration: CR H2373)
DEBATE - The House continued with debate on S. 524.
DEBATE - The House proceeded with one hour of debate on S. 524.
Rule provides for consideration of S. 524. Motion to recommit with or without instructions allowed. Bill is closed to amendments.
Considered under the provisions of rule H. Res. 725. (consideration: CR H2355-2374)
Rule H. Res. 725 passed House.
Rules Committee Resolution H. Res. 725 Reported to House. Rule provides for consideration of S. 524. Motion to recommit with or without instructions allowed. Bill is closed to amendments.
Held at the desk.
Received in the House.
Message on Senate action sent to the House.
Passed Senate with an amendment by Yea-Nay Vote. 94 - 1. Record Vote Number: 34. (text as passed Senate: CR S1404-1416)
SenatePassed/agreed to in Senate: Passed Senate with an amendment by Yea-Nay Vote. 94 - 1. Record Vote Number: 34.(text as passed Senate: CR S1404-1416)
SenateConsidered by Senate. (consideration: CR S1403-1416)
Cloture on the measure invoked in Senate by Yea-Nay Vote. 93 - 3. Record Vote Number: 33. (consideration: CR S1361; text: CR S1361)
SenateConsidered by Senate. (consideration: CR S1357-1384)
Considered by Senate. (consideration: CR S1328-1332, S1332-1341)
Considered by Senate. (consideration: CR S1303-1313)
Cloture motion on the measure presented in Senate. (consideration: CR S1273; text: CR S1273)
Considered by Senate. (consideration: CR S1245-1273)
The committee substitute withdrawn by Unanimous Consent. (consideration: CR S1180)
Measure laid before Senate by unanimous consent. (consideration: CR S1171-1218; text of measure as reported in Senate: CR S1171-1180)
Motion to proceed to consideration of measure agreed to in Senate by Unanimous Consent. (consideration: CR S1171)
Motion to proceed to measure considered in Senate. (consideration: CR S1106-1115, S1115-1132)
Cloture on the motion to proceed to the measure invoked in Senate by Yea-Nay Vote. 89 - 0. Record Vote Number: 27. (consideration: CR S1076; text: CR S1076)
SenateMotion to proceed to measure considered in Senate. (consideration: CR S1074-1080)
Cloture motion on the motion to proceed to the measure presented in Senate. (consideration: CR S1037-1038; text: CR S1037)
Motion to proceed to consideration of measure made in Senate. (consideration: CR S1037-1038)
Placed on Senate Legislative Calendar under General Orders. Calendar No. 369.
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Committee on the Judiciary. Hearings held.
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
| Referred to |
| February 12, 2015 |
| February 22, 2016 |
| Introduced in Senate | February 12, 2015 |
| Enrolled Bill | -- |
| Independent |
| VT |
| Bill Nelson | Democratic | FL |
| Brian Schatz | Democratic | HI |
| Charles E. Schumer | Democratic | NY |
| Christopher A. Coons | Democratic | DE |
| Chuck Grassley | Republican | IA |
| Claire McCaskill | Democratic | MO |
| Cory A. Booker | Democratic | NJ |
| Dan Sullivan | Republican | AK |
| Daniel Coats | Republican | IN |
| Debbie Stabenow | Democratic | MI |
| Dianne Feinstein | Democratic | CA |
| Elizabeth Warren | Democratic | MA |
| Jeanne Shaheen | Democratic | NH |
| Joe Donnelly | Democratic | IN |
| Joe Manchin, III | Independent | WV |
| John Boozman | Republican | AR |
| John Cornyn | Republican | TX |
| Jon Tester | Democratic | MT |
| Kelly Ayotte | Republican | NH |
| Kirsten E. Gillibrand | Democratic | NY |
| Lamar Alexander | Republican | TN |
| Lindsey Graham | Republican | SC |
| Lisa Murkowski | Republican | AK |
| Marco Rubio | Republican | FL |
| Mark Kirk | Republican | IL |
| Martin Heinrich | Democratic | NM |
| Mazie K. Hirono | Democratic | HI |
| Orrin G. Hatch | Republican | UT |
| Patrick J. Leahy | Democratic | VT |
| Richard Blumenthal | Democratic | CT |
| Richard J. Durbin | Democratic | IL |
| Rob Portman | Republican | OH |
| Robert Menendez | Democratic | NJ |
| Roy Blunt | Republican | MO |
| Shelley Moore Capito | Republican | WV |
| Susan M. Collins | Republican | ME |
| Tammy Baldwin | Democratic | WI |
| Thom Tillis | Republican | NC |
| Tim Kaine | Democratic | VA |
| Tom Udall | Democratic | NM |
| S 2872 |
114th |
| Related bill |
| S 2678 | 114th | Related bill |
| S 2256 | 114th | Related bill |
| S 1913 | 114th | Related bill |
| HRES 809 | 114th | Procedurally-related |
| HRES 725 | 114th | Procedurally-related |
| HR 953 | 114th | Identical bill |
| HR 5249 | 114th | Related bill |
| HR 5145 | 114th | Related bill |
| HR 5052 | 114th | Related bill |
| HR 5048 | 114th | Related bill |
| HR 5046 | 114th | Related bill |
| HR 4985 | 114th | Related bill |
| HR 4982 | 114th | Related bill |
| HR 4981 | 114th | Related bill |
| HR 4978 | 114th | Related bill |
| HR 4976 | 114th | Related bill |
| HR 4969 | 114th | Related bill |
| HR 4892 | 114th | Related bill |
| HR 4876 | 114th | Related bill |
| HR 4843 | 114th | Related bill |
| HR 4641 | 114th | Related bill |
| HR 4599 | 114th | Related bill |
| HR 4586 | 114th | Related bill |
| HR 4063 | 114th | Related bill |
| HR 3691 | 114th | Related bill |
| HR 3680 | 114th | Related bill |
| HR 3380 | 114th | Related bill |
| HR 2463 | 114th | Related bill |
| HR 1818 | 114th | Related bill |
| HR 1725 | 114th | Related bill |
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2018 · fourth_quarter · Health Issues
HCR: Implementation of health care reform law as it relates to substance abuse treatment and prevention, Medicaid - IMD exclusion; parity for SUD treatment;S.524 access to treatment under Medicaid and Essential Health benefits, the Comprehensive Addiction & Recovery Act, specifically provisions that relate to SUD Treatment. S.1169 Medcaid Coverage for Addiction Recovery Expansion (Medicaid CARE) act , H.R. 2938 Road to Recovery Act, H.R. 2687 Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act; monitor policies and regulations related to the President's declaration of the opioid crisis as a public health emergency under the Public Health Service Act; H.R. 5797 Legislation to reform the IMD exclusion; Provisions related to IMD exclusion in HR 6 Opioid Crisis Response Act and enacted into law as the SUPPORT for Patients and Communities Act, designated Public Law 115-271
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · third_quarter · Health Issues
HCR: Implementation of health care reform law as it relates to substance abuse treatment and prevention, Medicaid - IMD exclusion; parity for SUD treatment;S.524 access to treatment under Medicaid and Essential Health benefits, the Comprehensive Addiction & Recovery Act, specifically provisions that relate to SUD Treatment. S.1169 Medcaid Coverage for Addiction Recovery Expansion (Medicaid CARE) act , H.R. 2938 Road to Recovery Act, H.R. 2687 Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act; monitor policies and regulations related to the President's declaration of the opioid crisis as a public health emergency under the Public Health Service Act; H.R. 5797 Legislation to reform the IMD exclusion; Provisions related to IMD exclusion in HR 6 Opioid Crisis Response Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Alcohol and Drug Abuse
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $164,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
Implementation of health care reform law as it relates to substance abuse treatment and prevention, Medicaid - IMD exclusion; parity for SUD treatment;S. 524, ccess to treatment under Medicaid and Essential health benefits the Comprehensive Addiction & Recovery Act, specifically provisions that relate to SUD Treatment. S.1169 Medcaid Coverage for Addiction Recovery Expansion (Medicaid CARE) act , H.R. 2938 Road to Recovery Act, H.R. 2687 Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act; monitoring policies and regulations related to the Presidents declaration of the opioid crisis as a public health emergency under the Public Health Service Act; H.R. 5797 Legislation to reform IMD exclusion
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2018 · second_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · second_quarter · Alcohol and Drug Abuse
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $147,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
HCR: Implementation of health care reform law as it relates to substance abuse treatment and prevention, Medicaid - IMD exclusion; parity for SUD treatment;S.524 access to treatment under Medicaid and Essential Health benefits, the Comprehensive Addiction & Recovery Act, specifically provisions that relate to SUD Treatment. S.1169 Medcaid Coverage for Addiction Recovery Expansion (Medicaid CARE) act , H.R. 2938 Road to Recovery Act, H.R. 2687 Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act; monitor policies and regulations related to the President's declaration of the opioid crisis as a public health emergency under the Public Health Service Act; H.R. 5797 Legislation to reform the IMD exclusion
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · first_quarter · Alcohol and Drug Abuse
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $178,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
Reducing opioid overdose deaths; implementation of HR 3680/S. 2256 provisions related to naloxone included in the conference report on S. 524, the Comprehensive Addiction and Recovery Act S.771 Improving Access to Affordable Prescription Drugs Act, S.469 Affordable and Safe Prescription Drug Importation Act; monitoring policies and regulations related to the President's declaration of the opioid crisis as a public health emergency under the Public Health Service Act
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
2017 · fourth_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · fourth_quarter · Health Issues
Reducing opioid overdose deaths; implementation of HR 3680/S. 2256 provisions related to naloxone included in the conference report on S. 524, the Comprehensive Addiction and Recovery Act S.771 Improving Access to Affordable Prescription Drugs Act, S.469 Affordable and Safe Prescription Drug Importation Act; monitoring policies and regulations related to the President's declaration of the opioid crisis as a public health emergency under the Public Health Service Act
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
2017 · fourth_quarter · Health Issues
HCR: Implementation of health care reform law as it relates to substance abuse treatment and prevention, Medicaid - IMD exclusion; parity for SUD treatment; HR 2664 - Title V as it relates to Medicaid and the IMD exclusion and S. 1945 - Title V as it relates to Medicaid and the IMD Exclusion; S. 1949 and HR 2646 provisions that relate to the IMD exclusion and sud treatment; S. 524, and access to treatment under Medicaid and Essential Health benefits, the Comprehensive Addiction & Recovery Act, specifically provisions that relate to SUD Treatment. S.1169 Medcaid Coverage for Addiction Recovery Expansion (Medicaid CARE) act , H.R. 2938 Road to Recovery Act, H.R. 2687 Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act; monitor policies and regulations related to the President's declaration of the opioid crisis as a public health emergency under the Public Health Service Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
2017 · fourth_quarter · Alcohol and Drug Abuse
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $143,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Alcohol and Drug Abuse
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $143,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2017 · third_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · third_quarter · Health Issues
Reducing opioid overdose deaths; implementation of HR 3680/S. 2256 provisions related to naloxone included in the conference report on S. 524, the Comprehensive Addiction and Recovery Act S.771 Improving Access to Affordable Prescription Drugs Act, S.469 Affordable and Safe Prescription Drug Importation Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
2017 · third_quarter · Health Issues
HCR: Implementation of health care reform law as it relates to substance abuse treatment and prevention, Medicaid - IMD exclusion; parity for SUD treatment; HR 2664 - Title V as it relates to Medicaid and the IMD exclusion and S. 1945 - Title V as it relates to Medicaid and the IMD Exclusion; S. 1949 and HR 2646 provisions that relate to the IMD exclusion and sud treatment; S. 524, Graham Cassidy Substitute Amendment implementation of SUD treatment and access to treatment under Medicaid and Essential Health benefits, the Comprehensive Addiction & Recovery Act, specifically provisions that relate to SUD Treatment. S.1169 Medcaid Coverage for Addiction Recovery Expansion (Medicaid CARE) act , H.R. 2938 Road to Recovery Act, H.R. 2687 Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
2017 · third_quarter · Health Issues
HCR: Implementation of health care reform law as it relates to substance abuse treatment and prevention, Medicaid - IMD exclusion; parity for SUD treatment; HR 2664 - Title V as it relates to Medicaid and the IMD exclusion and S. 1945 - Title V as it relates to Medicaid and the IMD Exclusion; S. 1949 and HR 2646 provisions that relate to the IMD exclusion and sud treatment; S. 524, HR 1628, implementation of AHCA provisions related to SUD treatment and access to treatment under Medicaid and Essential Health benefits, the Comprehensive Addiction & Recovery Act, specifically provisions that relate to SUD Treatment. S.1169 Medcaid Coverage for Addiction Recovery Expansion (Medicaid CARE) act , H.R. 2938 Road to Recovery Act, H.R. 2687 Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
2017 · second_quarter · Health Issues
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · second_quarter · Alcohol and Drug Abuse
Issues related to DEA quotas of Schedule I and II controlled substances S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
Coverage and reimbursement policy for HCV and HIV portfolio S.524/H.R.953-The Comprehensive Addiction and Recovery Act (CARA)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Health Issues
Issues related to S. 1455/H.R. 2356, The Recovery Enhancement for Addiction Treatment (TREAT) Act. Issues related to S. 524/H.R. 4981, The Comprehensive Addiction and Recovery Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · second_quarter · Health Issues
Reducing opioid overdose deaths; implementation of HR 3680/S. 2256 provisions related to naloxone included in the conference report on S. 524, the Comprehensive Addiction and Recovery Act; Pharmaceutical drug development, including epinephrine for anaphylaxis. S.771 Improving Access to Affordable Prescription Drugs Act, S.469 Affordable And Safe Prescription Drug Importation Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
2017 · first_quarter · Pharmacy
Reducing opioid overdose deaths; implementation of HR 3680/S. 2256 provisions related to naloxone included in the conference report on S. 524, the Comprehensive Addiction and Recovery Act; Pharmaceutical drug development, including epinephrine for anaphylaxis.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
Reducing opioid overdose deaths; implementation of HR 3680/S. 2256 provisions related to naloxone included in the conference report on S. 524, the Comprehensive Addiction and Recovery Act; Pharmaceutical drug development, including epinephrine for anaphylaxis.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
Coverage and reimbursement policy for HCV and HIV portfolio S.524/H.R.953-The Comprehensive Addiction and Recovery Act (CARA)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Client expense: Not reported · Firm income: $14,500
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · first_quarter · Health Issues
Issues related to S. 1455/H.R. 2356, The Recovery Enhancement for Addiction Treatment (TREAT) Act. Issues related to S. 524/H.R. 4981, The Comprehensive Addiction and Recovery Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuse and diversion. Comprehensive Drug Addiction and Recovery Act (S. 524) Pharmacy issues within TriCARE Issues related to scope of services for pharmacists
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · first_quarter · Alcohol and Drug Abuse
Issues related to DEA quotas of Schedule I and II controlled substances S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Science/Technology
S. 524/H.R. 953 Comprehensive Addiction and Recovery Act S. 2011/S. 2014 Innovations for Healthier Americans Act H.Res. 725 To consider S. 524 to authorize the Attorney General to award grants to address prescription opioid abuse and heroin use. H.Res. 809 To consider the conference report to S. 524 to authorize the Attorney General to award grants to address prescription opioid abuse and heroin use FY2017 Department of Defense Appropriations Bills - funding for psychological research FY2018 Department of Defense Appropriations Bills - funding for psychological research FY2017 Commerce/Justice/Science Appropriations Bills - funding for psychological research FY2018 Commerce/Justice/Science Apprpriations Bills - funding for psychological research FY2018 Department of Veterans Affairs Appropriations Bills - funding for psychological research Marijuana Effective Drug Studies (MEDS) Act Cannabidiol Research Act Medical Marijuana Research Act
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2017 · first_quarter · Health Issues
Coverage and reimbursement policy for HCV and HIV portfolio S.524/H.R.953-The Comprehensive Addiction and Recovery Act (CARA)
Client expense: Not reported · Firm income: Not reported
2016 · third_quarter · Health Issues
Cures (HR 6) and Mental Health Reform Bill (HR 2646); Support for health IT interoperability, mental health integration and mental health parity. Interest in Medicaid. S 2943 - Urge conferees on NDAA S 2943 to drop Tricare telehealth provision: Preserve state license-Physician is site of telehealth care. HR 2577, HR 5243 HR 4973 - Public Health/Emergency Funding: Funding for Zika emergency response: Public Health. Comprehensive Addiction & Recovery Act (CARA PL 114-198, S 524 HR 953 HR 1725 HR 4981 HR 4599 HR 3680 HR 4586 HR 4969 HR 4641 HR 5046:Support state prescription drug monitoring, treatment, naloxone, take-backs, partial fil & evidence based prescribing & treatment. HR 5325 Continuing Appropriations and Military Construction, Veterans Affairs, Appropriation Act, 2017 and Zika Response and Preparedness Act: Zika public health response funding in FY 2016 & FY 2017. S. 3040; HR 5926 - HHS FY 17 Appropriations priorities: AHRQ, HRSA, Title VII, NHSC, Title X, CARA: AAFP federal spending priorities for primary care training research and access. No Bill No. - Graduate Medical Education - Explain and advocate for AAFP's policy proposals on GME. No Bill No.-Graduate Medical Education: Pursue advancement of a bill to fix problem caused by "rotators" who establish low caps and PRAs. No Bill No. - Physician Payment Reform: Advocate for introduction of a House companion bill to allow HSA population access to direct primary care (DPC). No Bill No. - Physician Payment Reform: draft letter of support for permanence in the Independence at Home Demonstration model. No Bill No.-Graduate Medical Education: Advocate for solution to VACAA Expansion slots - how to fill them with more family medicine residents. No Bill No. - Graduate Medical Education: Advocate for the introduction of a bill to help resolve problems specific to the rural GME. No Bill No. - Graduate Medical Education: Advocate for introduction of a Resolution to support the stability in the Teaching Health Center GME program. No Bill No. - FY2018 appropriations for HRSA Title VII 747: Primary Care Training and Enhancement Grants. No Bill No. - Encourage House members to join Primary Care Caucus: Increase membership of the Primary Care Caucus. No Bill No. - Advisory Committee on Training in Primary Care Medicine and Dentistry: Increase support for Title VII. No Bill No. - Injury and Violence Prevention Network bfg: Preventing injury and death are key to public health. No Bill No. - Transforming Primary Care for 21st Century THC, GME and NHSC. No Bill N0. - Teaching Health Center Graduate Medical Education permanence: Increasing primary care workforce; maintain the sustainability of the THCGME program. No Bill No. - National Advisory Council on the National Health Service Corps: Medical student debt relief, improved access to primary care. No Bill No. - Coalition for Health Funding - AAFP Health is Primary booth: Raising awareness of AAFP and value of primary care; increasing primary care workforce. No Bill No. Medication Assisted Treatment for Opioid Use Disorders rule comments: Reduce administrative burden and increase MAT patient limit. No Bill No. - Letter to VA on APRNs re Concern with APRN expansion. No Bill No. - Letter to VA nominating FPs: Advisory Comm. on Women Veterans. No Bill No. - Letter to HHS nominating FPs: Advisory Comm. on Minority Health. No Bill No. - Letter to CDC nominating FPs: Advisory Comm. to the Director. No Bill No. - Letter to SAMHSA on opioid use: Opioid use disorder reporting. No Bill No. - Letter to CDC nominating FPs: Infection advisory committee. No Bill No. - Letter to CMS on patient relationship categories and codes: How to implement patient relationship categories and codes as required by MACRA. No Bill No. - Letter to CMS on 2017 proposed Medicare physician fee schedule: Comments on the 2017 regulation. No Bill No. - Letter to CMS on ESRD payment models: Not replacing fragmented FFS with fragmented APMs. No Bill No. - Letter nominating FPs to MEDCAC: Medicare coverage. No Bill No. - Letter to HHS on opioid prescribing education: Required CME. No Bill No. - Letter to HHS on contraceptive services: Expanding the availability of contraceptives. No Bill No. - Letter to VA on protected patient info: Support for allowing HIV and sickle cell negative results to be transmitted. Non Bill No. - Nominating FPs to CDC Committee: Health disparities subcommittee. No Bill No. - GME: Support for Teaching Health Center reauthorization; Maintain the sustainability of the THCGME program. No Bill No. - Health IT/Interoperability/Cures: Support for Health IT and interoperability legislation. No Bill No. - Mental Health reform: Support mental health reform integration and mental health parity. No Bill No. - Chronic Disease Bill: Support for eliminating the chronic care managemnt codes copayment. No Bill No. - Drug Pricing: Expressed interest in drug pricing generally. No Bill No - FY 2016 appropriations AHRQ, HRSA Title VII, NHSC: AAFP Federal spending priorities to support workforce, research. No Bill No. - Graduate Medical Education - Explain and advocate for AAFP's policy proposals on GME. No Bill No. - Congressional Primary Care Caucus - Urge members to join the Caucus and support Primary Care to achieve the triple aim in health care. No Bill No. - National Defense Authorization Act: Remove national licensure provisions in NDAA legislation health provisions. No Bill No. - Health Insurance Marketplace Issues and Provider Involvement with Patient Enrollment: Network Adequacy, Patient Enrollment in Marketplaces. No Bill No. - Children's Health Insurance: CHIP/Medicaid. No Bill No. - Medicaid: Medicaid alternative proposals.
Client expense: $749,400 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA), White House Office
2016 · third_quarter · Alcohol and Drug Abuse
Comprehensive Addiction & Recovery Act (CARA PL 114-198, S 524 HR 953 HR 1725 HR 4981 HR 4599 HR 3680 HR 4586 HR 4969 HR 4641 HR 5046:Support state prescription drug monitoring, treatment, naloxone, take-backs, partial fil & evidence based prescribing & treatment. No Bill No. - Medication assisted Treatment for Opioid Use Disorders rule comments; reduce administrative burden and increase MAT patient limit.
Client expense: $749,400 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA), White House Office
2016 · second_quarter · Health Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention. Overdose Prevention Act, issues related to overdose prevention. S. 524, Comprehensive Addiction Recovery Act Issues related to federal syringe funding ban S. 683, CARERS Act, issues related to medical marijuana. H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention. Overdose Prevention Act, issues related to overdose prevention. S. 524, Comprehensive Addiction Recovery Act S. 683, CARERS Act, issues related to medical marijuana. H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Primary care; Medicare reimbursement; PA Hospice (HR 1202; S1354); Transparency; Mental health treatment; the chronic care workgroup; and Veterans health care; Opioid addiction treatment/chronic care. (S 524, S 1455, HR4396, HR 2646) Promoting access to diabetic shoes (HR 4756).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2016 · third_quarter · Health Issues
Support S 258 and HR 169, Critical Access Hospital Relief Act, a bill that would remove the 96-hour physician certification requirement as a condition of payment for critical access hospitals (CAHs); Support HR 293, a bill to exempt certain journals and text books used in continuing medical education (CME) from manufacturer transparency reporting requirements; Participated in the Hearing, Examining the 340B Drug Pricing Program and submitted testimony about the 340B program, a federal drug discount program to Subcommittee members who will review the functionality of the program to ensure it is meeting its intended goals; HR 6, 21st Century Cures, a bill that accelerates the discovery and development of cures, and also includes provisions addressing interoperability of health IT and would provide additional money to NIH and the FDA; Two midnight discussion with several members of Congress; Support, Advancing Telehealth Opportunities in Medicare Telehealth, submitted a letter outlining the benefits of telehealth and showcases successful hospital and health system efforts. It also outlines barriers to greater use of telehealth; Submitted letter pertaining to interoperabilty within the hospital communities; Support S. 599, Improving Access to Emergency Psychiatric Care Act of 2015, legislation easing the shortage of psychiatric beds and extend and expand the CMS emergency psychiatric demonstration project; Comments on H.R.1458, BACPAC Act of 2015, a bill to amend title XVIII of the Social Security Act to provide bundled payments for post-acute care services under parts A and B of Medicare, and submitted a statement for a hearing on HR 1458 (re bundled payments for post-acute and other post-hospital services); Discussed Equity of Care Issues with Members of Congress; Advocate for funding by working with the Office of the Assistant Secretary for Preparedness and Response (ASPR) and Hospital Preparedness Program staff on ensuring adequate Ebola hospital funding; Working with the Centers for Disease Control and Prevention (CDC) on ongoing Ebola-related issues and guidance; Working with the Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA) to ensure that hospitals continue to be able to use blood glucose monitoring systems (BGMS) on hospitalized patients;Discussion of draft guidance on drug compounding and repackaging; Working with ASPR and CDC staff to define the impact of the Hospital Preparedness Program and Public Health Emergency Preparedness Program on improving health care system preparedness; Support efforts to advocate on Ebola within a discussion with FDA regarding impact on access to chest tubes regarding the Atrium Medical Corp and Maquet consent decree ; Advocate for regulatory approach in a discussion with White House staff regarding new initiative promoting bystander involvement in stopping hemorrhage in injured civilians; Attended a roundtable discussion on Opioid-related dependence, overdose, and death at HHS; Advocate for changes to The Care Planning Act, a bill that would provide for advanced illness care coordination services for Medicare beneficiaries; Support HR 2878 and S 1461,a bill to provide for the extension of the enforcement instruction on supervision requirements for outpatient therapeutic services in critical access and small rural hospitals through 2015; Support S.799/HR 1462, Protecting Our Infants Act of 2015, a bill to combat the rise of prenatal opioid abuse and neonatal abstinence syndrome; Discussed S.1349, a bill that amends title XVIII (Medicare) of the Social Security Act to require a hospital or critical access hospital with an agreement with the Secretary of Health and Human Services to give each individual who receives observation services as an outpatient for more than 24 hours an adequate oral and written notification within 36 hours after beginning treatment; Supported expansions to Medicare reimbursement for telehealth along with changes to the Health Care Connect Fund; Comments on S.1648, Rural Emergency Acute Care Hospital Act of 2015, a bill to amend title XVIII of the Social Security Act to create a sustainable future for rural healthcare. Urged that HHS refrain from finalizing a stage 3 meaningful use rule; Advocate for Appropriate Surveyor Guidance on Calculated Hospitals in discussion about member concerns regarding remarks of CMS official that were confusing during a health lawyers association webinar; Discussion with CMS staff regarding proposed rule on establishing market-based payments for clinical laboratory tests; Discussion to rescind the proposed 2 percent cut to CY 2016 outpatient PPS conversion factor; Support H.R.2948, Medicare Telehealth Parity Act of 2015, a bill to amend title XVIII (Medicare) of the Social Security Act to expand telehealth coverage in three phases; Support HR 2646, Helping Families in Mental Health Crisis Act of 2015,A bill to make available needed psychiatric, psychological, and supportive services for individuals with mental illness and families in mental health crisis; Support HR 1604, Veterans Mental Health Care Access Act, a bill that expands access to mental health services for veterans; Support H.R. 3183, The Veterans Health Care Freedom Act, a bill which makes significant improvements to the Veterans Choice Program; Support S 1189 The Conrad State 30 and Physician Access Act, a bill that reauthorizes the Conrad 30 and makes other changes to the program to improve patient access to care; Discussed quality measurement, meaningful use and Conditions of Participation; Conversation with CMS about the IOM Vital Signs report and how its recommendations could make quality measurement more meaningful; Spoke with CMS urging the Agency to correct the misimpression that was created statements made during a National Association of Medical Staff Specialists webinar by a CMS employee; Discussion with CMS about proposals contained in the Inpatient Psychiatric Facility PPS proposed rule urging CMS not to finalize two quality measures; Meeting at CMMI to discuss CCJR; Discuss S. 2141the Transparent Ratings on Usability and Security to Transform Information Technology Act of 2015, the TRUST Act, a bill that includes a definition of information blocking and a framework to assess interoperability of certified health IT (a health IT ratings program); Support S.1461 and H.R. 2878 a bill to provide for the extension of the enforcement instruction on supervision requirements for outpatient therapeutic services in critical access and small rural hospitals through 2015; Oppose S. 1648 Rural Emergency Acute Care Hospital ActTo establish an alternative payment model for CAHs and small, rural hospitals whereby they may transition to become a rural emergency hospital.; Oppose H.R. 3225 Save Rural Hospitals Act, a bill to amend titles XVIII and XIX of the Social Security Act to provide for enhanced payments to rural health care providers under the Medicare and Medicaid programs; Discuss S. 1945 Mental Health Reform Act of 2015, a bill to make available needed psychiatric, psychological, and supportive services for individuals with mental illness and families in mental health crisis. It would reauthorize certain federal mental health programs, revise the IMD exclusion, reform SAMHSA, and study parity in mental health laws. Support S. 1893, The Mental Health Awareness and Improvement Act of 2015, a bill to reauthorize and improve programs related to mental health and substance use disorders; Letter asking for modifications to H.R. 3298 Medicare Post-Acute Care Value-Based Purchasing (PAC VBP) Act of 2015, the legislation would establish a value-based purchasing program for LTCHs, IRFs, SNFs and HH agencies. Worked to streamline and improve quality measures; Discussed how to implement the framework in the National Academy of Medicines Vital Signs report to streamline and focus quality measures used in Medicare programs; Discussed Opioid prescribing guidelines with the CDC to provide feedback on the opioid prescribing guidelines they were developing; Discussion with CMS regarding CAH designation status, negative impact of Insurance Consolidations on Medicare Advantage and for modifications to Comprehensive Care for Joint Replacement (CJR) model regarding aspects of the proposed rule; Discussion with CMS about the Emergency Preparedness final rule; Discussion with CMS regarding the 0.2 percent reduction to hospitals payments under the Inpatient Prospective Payment System (PPS); Support S. 524, the Johnson amendment and the Collins amendment, Comprehensive Addiction and Recovery Act of 2016, a bill to authorize the Attorney General to award grants to address the national epidemics of prescription opioid abuse and heroin use; Support H.R. 4499, Promoting Responsible Opioid Prescribing Act of 2016, a bill to amend title XVIII of the Social Security Act to remove consideration of certain pain-related issues from calculations under the Medicare hospital value-based purchasing program; Support S. 2220, The Healthy Maternity and Obstetric Medicine Act or Healthy MOM Act guarantees maternity coverage for women who are enrolled in the exchanges established under the Affordable Care Act, as well as women who are covered by individual and group insurance plans and federal employee health benefit plans; Comments to House Ways and Means and Senate Finance Committees on how to improve the physician self-referral (Stark) law; Urged CMS to delay the April 2016 release of the hospital star ratings on the Hospital Compare Website; Supported House and Senate letters urging CMS to delay release of hospital star ratings on the Hospital Compare Website; Support H.R. 4771, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act, a bill that would reduce health care costs and promote access to quality, affordable health care for all Americans; Letter to Senate HELP Committee draft legislation addressing health information technology (IT) and electronic health records (EHRs); Comments to CMS regarding addressing section 603 of the BBA of 2015 in regulation; Comments to House Energy & Commerce Committee regarding section 603 of the BBA of 2015 as well as site neutral payment policies in general; Statement for the record to House Energy & Commerce Committee on MACRA implementation; Statement for the record to Senate Finance Committee on MACRA implementation; Comments to the Senate Finance Committee Chronic Care document -Conversations with the CDC related to their opioid guidelines for chronic pain as well as a patient education piece about opioids; Discussions with CMS about CAH designation status Health Care Issues; Discussions with Rep. Hudson about H.R. 4365/ S. 2932, the Protecting Patient Access to Emergency Medications Act , a bill to amend the Controlled Substances Act with regard to the provision of emergency medical services; Support H.R. 4650 and S. 2108, Preserving Patient Access to Post-Acute Hospital Care Act of 2016, a bill to amend title XVIII of the Social Security Act to provide for an extension of certain Medicare long-term care hospital payment rules; Supported efforts to encourage Congress to send CMS letters on addressing the issue of colocation of facilities within a hospital; Discussions with Members of Congress on the potential implementation of Unique Device Identification on claims forms; Sponsored a Hill briefing on innovations in post-acute care;Supported House and Senate letters to CMS asking for flexibility when interpreting section 603 of the BBA of 2015 in regulation; Support HR 5547, the Health Care Price Transparency Promotion Act of 2016, a bill to require the sharing of health care price information; Support HR 5273, the Helping Hospitals Improve Patient Care Act of 2016, a bill to address outstanding issues with section 603 of the BBA of 2015 and provide for a socioeconomic adjustment to the Hospital Readmissions Reduction Program; Supported a letter to CMS on implementation of Sec. 603 of the Bipartisan Budget Acts site neutral cuts for off-campus HOPDs; Support H. res. 699 promoting minority health awareness and supporting the goals and ideals of National Minority Health Month in April 2016; Support H.R.4641 - a bill to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication; Support H.R. 4982, the Examining Opioid Treatment Infrastructure Act of 2016, a bill which would require the Government Accountability Office (GAO) to evaluate and report on the capacity, availability and need for inpatient and outpatient treatment for opioid use disorders in the United States; Supports H.R. 3680, the Co-Prescribing to Reduce Overdoses Act of 2015, a bill would establish federal grants to carry out co-prescribing of overdose reversal drugs in areas experiencing significant numbers of opioid overdoses and deaths; Support H.R. 3691, the Improving Treatment for Pregnant and Postpartum Women Act of 2015, a bill that would reauthorize essential residential treatment programs for pregnant and postpartum women and provide grants to states to address the growing epidemic of infants suffering from opioid dependency; Support H.R. 4978, the Nurturing and Supporting Healthy Babies Act, a bill which would require a GAO evaluation of neonatal abstinence syndrome and the availability of treatment for this condition in the nations Medicaid programs; Support H.R. 4599, the Reducing Unused Medications Act of 2016, a bill to permit partial filling of schedule II prescriptions under specific circumstances; Support H.R. 4976, the Opioid Review Modernization Act of 2016, a bill which would provide for more stringent Food and Drug Administration review of new opioids without abuse-deterrent properties, recommendations for labeling of pediatric opioids, and recommendations for prescriber education; Support the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016, a bill for achieving fair and sustainable drug pricing; Supporting full alignment of 42CFR substance use records confidentiality requirements with HIPAA privacy rule; Support S. 3173 EHR Regulatory Relief Act, a bill to amend title XVIII of the Social Security Act to provide for a 90-day EHR reporting period for the determination of whether an eligible professional or eligible hospital is a meaningful EHR user and to remove the all-or-nothing approach to meaningful use; Support for H.R. 5713, The Sustaining Healthcare Integrity and Fair Treatment Act of 2016, a bill that would extend 25% rule relief and provide targeted relief to certain LTCHs struggling to meet the new criteria standards; Support for H.R. 6174, the Closing Loopholes for Orphan Drugs Act, a bill to amend title III of the Public Health Service Act to limit the orphan drug exclusion under the drug discount program under section 340B of such title.
Client expense: $4,050,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · second_quarter · Health Issues
Support S 258 and HR 169, Critical Access Hospital Relief Act, a bill that would remove the 96-hour physician certification requirement as a condition of payment for critical access hospitals (CAHs); Support HR 293, a bill to exempt certain journals and text books used in continuing medical education (CME) from manufacturer transparency reporting requirements; Participated in the Hearing, Examining the 340B Drug Pricing Program and submitted testimony about the 340B program, a federal drug discount program to Subcommittee members who will review the functionality of the program to ensure it is meeting its intended goals; HR 6, 21st Century Cures, a bill that accelerates the discovery and development of cures, and also includes provisions addressing interoperability of health IT and would provide additional money to NIH and the FDA; Two midnight discussion with several members of Congress; Support, Advancing Telehealth Opportunities in Medicare Telehealth, submitted a letter outlining the benefits of telehealth and showcases successful hospital and health system efforts. It also outlines barriers to greater use of telehealth; Submitted letter pertaining to interoperabilty within the hospital communities; Support S. 599, Improving Access to Emergency Psychiatric Care Act of 2015, legislation easing the shortage of psychiatric beds and extend and expand the CMS emergency psychiatric demonstration project; Comments on H.R.1458, BACPAC Act of 2015, a bill to amend title XVIII of the Social Security Act to provide bundled payments for post-acute care services under parts A and B of Medicare, and submitted a statement for a hearing on HR 1458 (re bundled payments for post-acute and other post-hospital services); Discussed Equity of Care Issues with Members of Congress; Advocate for funding by working with the Office of the Assistant Secretary for Preparedness and Response (ASPR) and Hospital Preparedness Program staff on ensuring adequate Ebola hospital funding; Working with the Centers for Disease Control and Prevention (CDC) on ongoing Ebola-related issues and guidance; Working with the Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA) to ensure that hospitals continue to be able to use blood glucose monitoring systems (BGMS) on hospitalized patients;Discussion of draft guidance on drug compounding and repackaging; Working with ASPR and CDC staff to define the impact of the Hospital Preparedness Program and Public Health Emergency Preparedness Program on improving health care system preparedness; Support efforts to advocate on Ebola within a discussion with FDA regarding impact on access to chest tubes regarding the Atrium Medical Corp and Maquet consent decree ; Advocate for regulatory approach in a discussion with White House staff regarding new initiative promoting bystander involvement in stopping hemorrhage in injured civilians; Attended a roundtable discussion on Opioid-related dependence, overdose, and death at HHS; Advocate for changes to The Care Planning Act, a bill that would provide for advanced illness care coordination services for Medicare beneficiaries; Support HR 2878 and S 1461,a bill to provide for the extension of the enforcement instruction on supervision requirements for outpatient therapeutic services in critical access and small rural hospitals through 2015; Support S.799/HR 1462, Protecting Our Infants Act of 2015, a bill to combat the rise of prenatal opioid abuse and neonatal abstinence syndrome; Discussed S.1349, a bill that amends title XVIII (Medicare) of the Social Security Act to require a hospital or critical access hospital with an agreement with the Secretary of Health and Human Services to give each individual who receives observation services as an outpatient for more than 24 hours an adequate oral and written notification within 36 hours after beginning treatment; Supported expansions to Medicare reimbursement for telehealth along with changes to the Health Care Connect Fund; Comments on S.1648, Rural Emergency Acute Care Hospital Act of 2015, a bill to amend title XVIII of the Social Security Act to create a sustainable future for rural healthcare. Urged that HHS refrain from finalizing a stage 3 meaningful use rule; Advocate for Appropriate Surveyor Guidance on Calculated Hospitals in discussion about member concerns regarding remarks of CMS official that were confusing during a health lawyers association webinar; Discussion with CMS staff regarding proposed rule on establishing market-based payments for clinical laboratory tests; Discussion to rescind the proposed 2 percent cut to CY 2016 outpatient PPS conversion factor; Support H.R.2948, Medicare Telehealth Parity Act of 2015, a bill to amend title XVIII (Medicare) of the Social Security Act to expand telehealth coverage in three phases; Support HR 2646, Helping Families in Mental Health Crisis Act of 2015,A bill to make available needed psychiatric, psychological, and supportive services for individuals with mental illness and families in mental health crisis; Support HR 1604, Veterans Mental Health Care Access Act, a bill that expands access to mental health services for veterans; Support H.R. 3183, The Veterans Health Care Freedom Act, a bill which makes significant improvements to the Veterans Choice Program; Support S 1189 The Conrad State 30 and Physician Access Act, a bill that reauthorizes the Conrad 30 and makes other changes to the program to improve patient access to care; Discussed quality measurement, meaningful use and Conditions of Participation; Conversation with CMS about the IOM Vital Signs report and how its recommendations could make quality measurement more meaningful; Spoke with CMS urging the Agency to correct the misimpression that was created statements made during a National Association of Medical Staff Specialists webinar by a CMS employee; Discussion with CMS about proposals contained in the Inpatient Psychiatric Facility PPS proposed rule urging CMS not to finalize two quality measures; Meeting at CMMI to discuss CCJR; Discuss S. 2141the Transparent Ratings on Usability and Security to Transform Information Technology Act of 2015, the TRUST Act, a bill that includes a definition of information blocking and a framework to assess interoperability of certified health IT (a health IT ratings program); Support S.1461 and H.R. 2878 a bill to provide for the extension of the enforcement instruction on supervision requirements for outpatient therapeutic services in critical access and small rural hospitals through 2015; Oppose S. 1648 Rural Emergency Acute Care Hospital ActTo establish an alternative payment model for CAHs and small, rural hospitals whereby they may transition to become a rural emergency hospital.; Oppose H.R. 3225 Save Rural Hospitals Act, a bill to amend titles XVIII and XIX of the Social Security Act to provide for enhanced payments to rural health care providers under the Medicare and Medicaid programs; Discuss S. 1945 Mental Health Reform Act of 2015, a bill to make available needed psychiatric, psychological, and supportive services for individuals with mental illness and families in mental health crisis. It would reauthorize certain federal mental health programs, revise the IMD exclusion, reform SAMHSA, and study parity in mental health laws. Support S. 1893, The Mental Health Awareness and Improvement Act of 2015, a bill to reauthorize and improve programs related to mental health and substance use disorders; Letter asking for modifications to H.R. 3298 Medicare Post-Acute Care Value-Based Purchasing (PAC VBP) Act of 2015, the legislation would establish a value-based purchasing program for LTCHs, IRFs, SNFs and HH agencies. Worked to streamline and improve quality measures; Discussed how to implement the framework in the National Academy of Medicines Vital Signs report to streamline and focus quality measures used in Medicare programs; Discussed Opioid prescribing guidelines with the CDC to provide feedback on the opioid prescribing guidelines they were developing; Discussion with CMS regarding CAH designation status, negative impact of Insurance Consolidations on Medicare Advantage and for modifications to Comprehensive Care for Joint Replacement (CJR) model regarding aspects of the proposed rule; Discussion with CMS about the Emergency Preparedness final rule; Discussion with CMS regarding the 0.2 percent reduction to hospitals payments under the Inpatient Prospective Payment System (PPS); Support S. 524, the Johnson amendment and the Collins amendment, Comprehensive Addiction and Recovery Act of 2016, a bill to authorize the Attorney General to award grants to address the national epidemics of prescription opioid abuse and heroin use; Support H.R. 4499, Promoting Responsible Opioid Prescribing Act of 2016, a bill to amend title XVIII of the Social Security Act to remove consideration of certain pain-related issues from calculations under the Medicare hospital value-based purchasing program; Support S. 2220, The Healthy Maternity and Obstetric Medicine Act or Healthy MOM Act guarantees maternity coverage for women who are enrolled in the exchanges established under the Affordable Care Act, as well as women who are covered by individual and group insurance plans and federal employee health benefit plans; Comments to House Ways and Means and Senate Finance Committees on how to improve the physician self-referral (Stark) law; Urged CMS to delay the April 2016 release of the hospital star ratings on the Hospital Compare Website; Supported House and Senate letters urging CMS to delay release of hospital star ratings on the Hospital Compare Website; Support H.R. 4771, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act, a bill that would reduce health care costs and promote access to quality, affordable health care for all Americans; Letter to Senate HELP Committee draft legislation addressing health information technology (IT) and electronic health records (EHRs); Comments to CMS regarding addressing section 603 of the BBA of 2015 in regulation; Comments to House Energy & Commerce Committee regarding section 603 of the BBA of 2015 as well as site neutral payment policies in general; Statement for the record to House Energy & Commerce Committee on MACRA implementation; Statement for the record to Senate Finance Committee on MACRA implementation; Comments to the Senate Finance Committee Chronic Care document -Conversations with the CDC related to their opioid guidelines for chronic pain as well as a patient education piece about opioids; Discussions with CMS about CAH designation status Health Care Issues; Discussions with Rep. Hudson about H.R. 4365/ S. 2932, the Protecting Patient Access to Emergency Medications Act , a bill to amend the Controlled Substances Act with regard to the provision of emergency medical services; Support H.R. 4650 and S. 2108, Preserving Patient Access to Post-Acute Hospital Care Act of 2016, a bill to amend title XVIII of the Social Security Act to provide for an extension of certain Medicare long-term care hospital payment rules; Supported efforts to encourage Congress to send CMS letters on addressing the issue of colocation of facilities within a hospital; Discussions with Members of Congress on the potential implementation of Unique Device Identification on claims forms; Sponsored a Hill briefing on innovations in post-acute care;Supported House and Senate letters to CMS asking for flexibility when interpreting section 603 of the BBA of 2015 in regulation; Support HR 5547, the Health Care Price Transparency Promotion Act of 2016, a bill to require the sharing of health care price information; Support HR 5273, the Helping Hospitals Improve Patient Care Act of 2016, a bill to address outstanding issues with section 603 of the BBA of 2015 and provide for a socioeconomic adjustment to the Hospital Readmissions Reduction Program; Supported a letter to CMS on implementation of Sec. 603 of the Bipartisan Budget Acts site neutral cuts for off-campus HOPDs; Support H. res. 699 promoting minority health awareness and supporting the goals and ideals of National Minority Health Month in April 2016; Support H.R.4641 - a bill to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication; Support H.R. 4982, the Examining Opioid Treatment Infrastructure Act of 2016, a bill which would require the Government Accountability Office (GAO) to evaluate and report on the capacity, availability and need for inpatient and outpatient treatment for opioid use disorders in the United States; Supports H.R. 3680, the Co-Prescribing to Reduce Overdoses Act of 2015, a bill would establish federal grants to carry out co-prescribing of overdose reversal drugs in areas experiencing significant numbers of opioid overdoses and deaths; Support H.R. 3691, the Improving Treatment for Pregnant and Postpartum Women Act of 2015, a bill that would reauthorize essential residential treatment programs for pregnant and postpartum women and provide grants to states to address the growing epidemic of infants suffering from opioid dependency; Support H.R. 4978, the Nurturing and Supporting Healthy Babies Act, a bill which would require a GAO evaluation of neonatal abstinence syndrome and the availability of treatment for this condition in the nations Medicaid programs; Support H.R. 4599, the Reducing Unused Medications Act of 2016, a bill to permit partial filling of schedule II prescriptions under specific circumstances; Support H.R. 4976, the Opioid Review Modernization Act of 2016, a bill which would provide for more stringent Food and Drug Administration review of new opioids without abuse-deterrent properties, recommendations for labeling of pediatric opioids, and recommendations for prescriber education; Support the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016, a bill for achieving fair and sustainable drug pricing; Supporting full alignment of 42CFR substance use records confidentiality requirements with HIPAA privacy rule.
Client expense: $4,690,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
2016 · third_quarter · Health Issues
Senate Working Group on Innovation for Healthier Americans Prescription drug diversion and abuse S. 524, Comprehensive Addiction and Recovery Act of 2015, all provisions S. 2680, Mental Health Reform Act of 2016, all provisions S. 1945, Mental Health Reform Act of 2015, all provisions Mental health initiatives (H.R. 2646, Helping Families in Mental Health Crisis Act of 2016; S. 1945, Mental Health Reform Act of 2015); Health information technology - meaningful use; Senate HELP Committee's Working Group on Innovations; Zika funding; H.R. 6, 21st Century Cures Act; H.R. 5325, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.
Client expense: $1,640,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2016 · fourth_quarter · Science/Technology
S. 524/H.R. 953 Comprehensive Addiction and Recovery Act S. 2011/S. 2014 Innovations for Healthier Americans Act S. 3077 Marijuana Effective Drug Studies (MEDS) Act S. 3269 Cannabidiol Research Act H.R. 6 21st Century Cures Act and Senate version H.R. 5549 Medical Marijuana Research Act H.Res. 725 To consider S. 524 to authorize the Attorney General to award grants to address prescription opioid abuse and heroin use. H.Res. 809 To consider the conference report to S. 524 to authorize the Attorney General to award grants to address prescription opioid abuse and heroin use FY2017 Department of Defense Appropriations Bills - funding for psychological research FY2017 Commerce/Justice/Science Appropriations Bills - funding for psychological research FY2017 Department of Veterans Affairs Appropriations Bills - funding for psychological research
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office